138 related articles for article (PubMed ID: 30383696)
1. Prevalence of monoclonal gammopathy of uncertain significance in chronic myeloid leukemia: A case report.
Ouyang W; Zhao X; Lu S; Wang Z
Medicine (Baltimore); 2018 Nov; 97(44):e13103. PubMed ID: 30383696
[TBL] [Abstract][Full Text] [Related]
2. Case Report: IgG multiple myeloma and chronic myeloid leukemia in a single patient.
Swaminathan N; Gupta S; Dourado C
F1000Res; 2020; 9():488. PubMed ID: 33042520
[TBL] [Abstract][Full Text] [Related]
3. Improvement of immune thrombocytopenia with imatinib therapy following chronic myeloid leukemia.
Nakamura Y; Itoh Y; Wakimoto N
Int J Hematol; 2023 Apr; 117(4):613-617. PubMed ID: 36374396
[TBL] [Abstract][Full Text] [Related]
4. Uncommon case of chronic myeloid leukemia with multiple myeloma.
Ide M; Kuwahara N; Matsuishi E; Kimura S; Gondo H
Int J Hematol; 2010 May; 91(4):699-704. PubMed ID: 20352382
[TBL] [Abstract][Full Text] [Related]
5. Nonsystemic vasculitic neuropathy in a patient with IgG-monoclonal gammopathy of undetermined significance: A case report.
Kinno R; Osakabe Y; Takahashi S; Kurokawa S; Owan Y; Ono K; Baba Y
Medicine (Baltimore); 2020 Jan; 99(5):e19036. PubMed ID: 32000451
[TBL] [Abstract][Full Text] [Related]
6. [Imatinib is effective in a 12-month-old boy with chronic myelogenous leukemia: case report and literature review].
Pan Y; Wen S; Tian J; Lyu Z; Du Z; Yan L
Zhonghua Er Ke Za Zhi; 2015 Mar; 53(3):194-7. PubMed ID: 26165016
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and Clinical Characteristics of Paraproteinemia Associated with Chronic Myeloid Leukemia.
Berger T; Shacham Abulafia A; Shimony S; Pasvolsky O; Vaxman I; Miron Y; Feldman S; Leader A; Raanani P
Acta Haematol; 2022; 145(6):619-626. PubMed ID: 35908535
[TBL] [Abstract][Full Text] [Related]
8. Role of autoimmune hemolytic anemia as an initial indicator for chronic myeloid leukemia: A case report.
Li X; Cai S; Zhong Z; Wang H; Wang L; You Y; Zhang M
Medicine (Baltimore); 2020 Feb; 99(9):e19256. PubMed ID: 32118733
[TBL] [Abstract][Full Text] [Related]
9. [Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014 ].
Adam Z; Krejčí M; Pour L; Sevčíková E; Křivanová A; Rehák Z; Koukalová R; Cermáková Z; Vaníček J; Sevčíková S
Vnitr Lek; 2014 Oct; 60(10):861-79. PubMed ID: 25382009
[TBL] [Abstract][Full Text] [Related]
10. Chronic Myeloid Leukemia in a Patient with Previous Idiopathic Thrombocytopenic Purpura: How to Manage Imatinib Together with Eltrombopag.
Autore F; Sora' F; Chiusolo P; Minnella G; Colangelo M; Rossi E; Sica S
Medicina (Kaunas); 2021 Dec; 57(12):. PubMed ID: 34946271
[TBL] [Abstract][Full Text] [Related]
11. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience.
Braziel RM; Launder TM; Druker BJ; Olson SB; Magenis RE; Mauro MJ; Sawyers CL; Paquette RL; O'Dwyer ME
Blood; 2002 Jul; 100(2):435-41. PubMed ID: 12091333
[TBL] [Abstract][Full Text] [Related]
12. Development of plasma cell leukemia in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate.
Maral S; Bakanay SM; Yikilmaz AS; Dilek I
J Cancer Res Ther; 2018; 14(6):1431-1433. PubMed ID: 30488870
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of lymphoid blastic crisis in chronic myelogenous leukemia with the additional bcr/abl transcript using imatinib-combined chemotherapy and high-dose chemotherapy with allogeneic bone marrow stem cell transplantation.
Kawano N; Okuda S; Yoshida S; Kugimiya H; Ito M; Horikawa N; Chosa N; Hisakata T; Fukudome T; Sakurai R; Yamashita K; Ueda A; Kanda Y
Int J Hematol; 2011 Dec; 94(6):561-6. PubMed ID: 22057509
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia.
Mat Yusoff Y; Abu Seman Z; Othman N; Kamaluddin NR; Esa E; Zulkiply NA; Abdullah J; Zakaria Z
Asian Pac J Cancer Prev; 2018 Dec; 19(12):3317-3320. PubMed ID: 30583336
[TBL] [Abstract][Full Text] [Related]
15. Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisolone for its management.
Ikuta K; Torimoto Y; Jimbo J; Inamura J; Shindo M; Sato K; Tokusashi Y; Miyokawa N; Kohgo Y
Int J Hematol; 2005 Nov; 82(4):343-6. PubMed ID: 16298828
[TBL] [Abstract][Full Text] [Related]
16. Type I cryoglobulinemic vasulitis with eosinophilia: A case report and literature review.
Wen J; Xu F; Li M; Zhou Q; Qu W; Liu Y; Su J; Hu H
Medicine (Baltimore); 2019 Jul; 98(28):e16382. PubMed ID: 31305439
[TBL] [Abstract][Full Text] [Related]
17. Factors Affecting Early Molecular Response in Chronic Myeloid Leukemia.
Chikkodi SV; Malhotra P; Naseem S; Khadwal A; Prakash G; Sahu KK; Kumari S; Suri V; Varma N; Varma S
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S114-9. PubMed ID: 26297263
[TBL] [Abstract][Full Text] [Related]
18. Hematopathologic and cytogenetic findings in imatinib mesylate treated chronic myelogenous leukemia patients: 2.5 years' experience.
Cojbasić I; Macukanović-Golubović L
Vojnosanit Pregl; 2010 Oct; 67(10):802-6. PubMed ID: 21061842
[TBL] [Abstract][Full Text] [Related]
19. Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.
Akram AM; Iqbal Z; Akhtar T; Khalid AM; Sabar MF; Qazi MH; Aziz Z; Sajid N; Aleem A; Rasool M; Asif M; Aloraibi S; Aljamaan K; Iqbal M
Cancer Biol Ther; 2017 Apr; 18(4):214-221. PubMed ID: 28278078
[TBL] [Abstract][Full Text] [Related]
20. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
